Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Summary
To assess the efficacy of HRS9531 injection compared with placebo in weight reduction in overweight or obese subjects after 36 weeks of treatment.
Official title: A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Overweight or Obese Subjects
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
61
Start Date
2023-10-16
Completion Date
2024-09-09
Last Updated
2026-05-22
Healthy Volunteers
No
Conditions
Interventions
HRS9531 injection
HRS9531 injection , QW,36 weeks
HRS9531 injection Placebo
HRS9531 injection Placebo,QW,36 weeks
Locations (4)
The Affiliated Hospital of Xuzhou Medicine University
Xuzhou, Jiangsu, China
Jinan Central Hospital
Jinan, Shandong, China
Zhejiang Hospital
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine
Hangzhou, Zhejiang, China